Hologic (NASDAQ:HOLX) was downgraded by equities researchers at Deutsche Bank from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday, Marketbeat reports. They currently have a $49.00 price objective on the medical equipment provider’s stock. Deutsche Bank’s price target points to a potential upside of 12.75% from the stock’s previous close.
A number of other equities research analysts also recently issued reports on HOLX. Royal Bank of Canada reissued a “hold” rating and issued a $42.00 target price on shares of Hologic in a research note on Friday, September 22nd. Needham & Company LLC reissued a “buy” rating and issued a $50.00 target price on shares of Hologic in a research note on Monday, October 2nd. Zacks Investment Research cut Hologic from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. Stifel Nicolaus reissued a “buy” rating and issued a $45.00 target price (down previously from $48.00) on shares of Hologic in a research note on Monday, October 9th. Finally, Jefferies Group reissued a “buy” rating and issued a $44.00 target price (down previously from $49.00) on shares of Hologic in a research note on Tuesday, October 10th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $48.79.
Hologic (NASDAQ:HOLX) traded down $0.39 during trading hours on Friday, hitting $43.46. The company’s stock had a trading volume of 4,360,000 shares, compared to its average volume of 1,870,544. The stock has a market capitalization of $12,088.73, a P/E ratio of 16.46, a P/E/G ratio of 2.09 and a beta of 0.95. Hologic has a 12-month low of $35.76 and a 12-month high of $46.80. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.79.
In other Hologic news, VP Karleen Marie Oberton sold 1,023 shares of the firm’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $39.84, for a total value of $40,756.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Elaine Ullian sold 9,282 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $40.50, for a total transaction of $375,921.00. The disclosure for this sale can be found here. Insiders sold 12,099 shares of company stock worth $487,223 over the last three months. 0.79% of the stock is owned by insiders.
Hedge funds have recently added to or reduced their stakes in the company. Koch Industries Inc. raised its holdings in Hologic by 15,554.1% in the 2nd quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock worth $1,125,000 after acquiring an additional 1,142,138 shares during the last quarter. Picton Mahoney Asset Management raised its holdings in Hologic by 8.1% in the 2nd quarter. Picton Mahoney Asset Management now owns 57,150 shares of the medical equipment provider’s stock worth $2,593,000 after acquiring an additional 4,300 shares during the last quarter. Chevy Chase Trust Holdings Inc. raised its holdings in Hologic by 1.4% in the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 244,620 shares of the medical equipment provider’s stock worth $8,975,000 after acquiring an additional 3,391 shares during the last quarter. Cipher Capital LP raised its holdings in Hologic by 57.9% in the 3rd quarter. Cipher Capital LP now owns 117,673 shares of the medical equipment provider’s stock worth $4,317,000 after acquiring an additional 43,146 shares during the last quarter. Finally, Janus Henderson Group PLC raised its holdings in Hologic by 15.5% in the 3rd quarter. Janus Henderson Group PLC now owns 285,035 shares of the medical equipment provider’s stock worth $10,458,000 after acquiring an additional 38,283 shares during the last quarter. Hedge funds and other institutional investors own 97.58% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Hologic (HOLX) Lowered to Hold at Deutsche Bank” was first posted by American Banking and Market News and is the sole property of of American Banking and Market News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/20/hologic-holx-lowered-to-hold-at-deutsche-bank.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
